| Neurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis T Chitnis, C Gonzalez, BC Healy, S Saxena, M Rosso, C Barro, ... Annals of clinical and translational neurology 5 (12), 1478-1491, 2018 | 140 | 2018 |
| MicroRNA-146a limits tumorigenic inflammation in colorectal cancer LP Garo, AK Ajay, M Fujiwara, G Gabriely, R Raheja, C Kuhn, B Kenyon, ... Nature communications 12 (1), 2419, 2021 | 80 | 2021 |
| Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis C Barro, BC Healy, Y Liu, S Saxena, A Paul, M Polgar-Turcsanyi, ... Neurology: Neuroimmunology & Neuroinflammation 10 (1), e200052, 2022 | 52 | 2022 |
| Temporal association of sNfL and gad‐enhancing lesions in multiple sclerosis M Rosso, CT Gonzalez, BC Healy, S Saxena, A Paul, K Bjornevik, J Kuhle, ... Annals of clinical and translational neurology 7 (6), 945-955, 2020 | 38 | 2020 |
| Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4 L Pandit, LM Cox, C Malli, A D'Cunha, T Rooney, H Lokhande, V Willocq, ... Neurology: Neuroimmunology & Neuroinflammation 8 (1), e907, 2020 | 32 | 2020 |
| Adipokines are associated with pediatric multiple sclerosis risk and course K Keyhanian, S Saxena, G Gombolay, BC Healy, M Misra, T Chitnis Multiple sclerosis and related disorders 36, 101384, 2019 | 23 | 2019 |
| microRNA-92a promotes CNS autoimmunity by modulating the regulatory and inflammatory T cell balance M Fujiwara, R Raheja, LP Garo, AK Ajay, R Kadowaki-Saga, ... The Journal of clinical investigation 132 (10), 2022 | 20 | 2022 |
| Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options M Rosso, S Saxena, T Chitnis Expert Review of Neurotherapeutics 20 (5), 509-516, 2020 | 16 | 2020 |
| Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes KB Holroyd, BC Healy, S Conway, M Houtchens, R Bakshi, ... Multiple sclerosis and related disorders 67, 104079, 2022 | 12 | 2022 |
| Identification of TNFAIP3 as relapse biomarker and potential therapeutic target for MOG antibody associated diseases S Saxena, H Lokhande, G Gombolay, R Raheja, T Rooney, T Chitnis Scientific Reports 10 (1), 12405, 2020 | 12 | 2020 |
| Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis K Galetta, C Deshpande, BC Healy, B Glanz, M Ziehn, S Saxena, A Paul, ... Annals of Clinical and Translational Neurology 8 (3), 631-638, 2021 | 10 | 2021 |
| MRI lesion state modulates the relationship between serum neurofilament light and age in multiple sclerosis M Rosso, BC Healy, S Saxena, A Paul, K Bjornevik, J Kuhle, P Benkert, ... Journal of Neuroimaging 31 (2), 388-393, 2021 | 10 | 2021 |
| Serum NfL but not GFAP predicts cognitive decline in active progressive multiple sclerosis patients C Barro, BC Healy, S Saxena, BI Glanz, A Paul, M Polgar-Turcsanyi, ... Multiple Sclerosis Journal 29 (2), 206-211, 2023 | 9 | 2023 |
| Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS H Lokhande, M Rosso, S Tauhid, R Chu, BC Healy, S Saxena, C Barro, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 8 (1 …, 2022 | 8 | 2022 |
| Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4. Neurol Neuroimmunol Neuroinflamm 2021; 8 (1): e907 L Pandit, LM Cox, C Malli, A D’Cunha, T Rooney, H Lokhande, V Willocq, ... Epub 2020/11/06. doi: 10.1212/NXI. 0000000000000907. PubMed PMID: 33148687, 0 | 8 | |
| Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects T Chitnis, BJ Kaskow, J Case, K Hanus, Z Li, JF Varghese, BC Healy, ... Frontiers In Immunology 13, 956907, 2022 | 6 | 2022 |
| Early neurofilament light and glial fibrillary acidic protein levels improve predictive models of multiple sclerosis outcomes G Bose, BC Healy, S Saxena, F Saleh, A Paul, C Barro, HA Lokhande, ... Multiple Sclerosis and Related Disorders 74, 104695, 2023 | 5 | 2023 |
| Development of a custom multivariate proteomic serum based assay for association with radiographic and clinical endpoints in MS T Chitnis, M Becich, R Bove, BAC Cree, V Gehman, R Gomez, ... Mult Scler, 148-148, 2020 | 5 | 2020 |
| Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine S Conway, S Saxena, C Baecher-Allan, R Krishnan, M Houtchens, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 9 (2 …, 2023 | 4 | 2023 |
| Clinical validation of a multi-protein, Serum-based assay for disease activity assessments in multiple sclerosis T Chitnis, J Foley, C Ionete, NK El Ayoubi, S Saxena, P Gaitan-Walsh, ... Clinical Immunology 253, 109688, 2023 | 3 | 2023 |
Tanuja ChitnisProfessor of Neurology, Harvard Medical SchoolVerified email at rics.bwh.harvard.edu
